Company attributes
Venture Capital Firm attributes
Other attributes
Longitude Capital is a venture capital firm in California that focuses on biotechnology and medical technology companies. Founded 2006 in Menlo Park, California, United States by David Hirsch, Marc Galletti, and Patrick Enright, it invests in debt, early stage ventures, late stage ventures, private equity, series A, post-IPO equity, and series B rounds. Its portfolio companies include SutroVax, Amunix, Epirium Bio, Poseida Therapeutics, Talaris Therapeutics, Inozyme, Encore Dermatology, Tiburio Therapeutics, 89bio and CuraSen Therapeutics. As of April 2020, Longitude Capital has made 71 investments. Their most recent investment was on March 6, 2020, when SutroVax raised $110M. Longitude Capital has had 21 exits, the most notable of which include Aimmune Therapeutics, Practice Fusion, and Axonics Modulation Technologies. the company has raised six funds, their latest being Longitude Venture Partners IV, L.p. This fund was announced on September 23, 2019 and raised a total of $550M.
